RxDoctor Payments Data

Albert Smith, DO

Family Medicine · Lapeer, MINPI 1366544280

Payments from drug & device makers

$9,144in general payments, 2019–2025

Across 583 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Novo Nordisk$1K
  • AbbVie$709
  • Lilly USA, LLC$685
  • Sanofi-aventis U.S. LLC$674
  • Bayer$477
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$9,113100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,144 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$142,054
Medicare patients
277
Services billed
25,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin575$516,767
OzempicSemaglutide247$372,159
EliquisApixaban222$256,324
JanuviaSitagliptin Phosphate105$135,149
MounjaroTirzepatide81$96,851
Enbrel SureclickEtanercept11$79,089
Dupixent PenDupilumab19$67,982
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$62,794
FarxigaDapagliflozin Propanediol51$58,197
Repatha SureclickEvolocumab63$54,758
ProliaDenosumab28$45,903
ArexvyRsvpref3 Antigen/As01e/Pf121$38,444
TrulicityDulaglutide22$29,780
Nurtec OdtRimegepant Sulfate27$26,352
InvokanaCanagliflozin19$23,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$429$516,767575 claims
Novo NordiskOzempic$1,080$372,159247 claims
PfizerEliquis, Nurtec Odt$255$282,677249 claims
MerckJanuvia$83$135,149105 claims
Lilly USA, LLCMounjaro, Trulicity$685$126,631103 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$107$116,934265 claims
AstraZenecaFarxiga$267$58,19751 claims
AmgenProlia$1,543$45,90328 claims
AbbVieUbrelvy, Qulipta$709$28,39235 claims
Johnson & JohnsonInvokana$293$23,17219 claims
Astellas Pharma US IncMyrbetriq$231$13,15119 claims
Sanofi-aventis U.S. LLCLantus$674$4,70828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Lapeer

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →